Xention Overview

  • Founded
  • 2002
Founded
  • Status
  • Private
  • Employees
  • 13
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 11

Xention General Information

Description

Developer of novel therapies created for the treatment of atrial fibrillation. The company develops drug candidates that modulate two novel but well-characterized, ion channels to develop breakthrough products in this area of huge unmet medical need, providing the healthcare industry with channel-modulating drugs for the treatment of atrial fibrillation, overactive bladder, pain and autoimmune diseases.

Contact Information

Website
Formerly Known As
Xention Discovery
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 38 High Street
  • Newmarket
  • Suffolk CB8 8LB
  • England, United Kingdom
+44 01223 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Xention Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Secondary Transaction - Private 000.00 Completed Generating Revenue
8. Later Stage VC 00.000 000.00 Completed Generating Revenue
7. Later Stage VC 18-Oct-2012 00.000 000.00 0000 Completed Generating Revenue
6. Later Stage VC (Series D) 23-Nov-2010 000.00 000.00 Completed Generating Revenue
5. Later Stage VC 25-Jun-2010 000.00 Completed Generating Revenue
4. Later Stage VC 31-Mar-2008 000.00 Completed Generating Revenue
3. Early Stage VC 18-Jul-2005 000.00 000.00 Completed Startup
2. Early Stage VC 10-Sep-2003 $6.34M $12.6M Completed Startup
1. Early Stage VC 01-Aug-2002 $6.24M $6.24M Completed Startup
To view Xention’s complete valuation and funding history, request access »

Xention Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
D Preferred 0,000,000 00.000000 00.0 00.0 00 00.0 00.000
To view Xention’s complete cap table history, request access »

Xention Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of novel therapies created for the treatment of atrial fibrillation. The company develops drug candidates that
Drug Discovery
Suffolk, United Kingdom
13 As of 2016
000.00
000000 - 000 000.00

00000000

modo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugi
0000 000000000
Brighton, United Kingdom
00 As of 0000
000.00
00000000000 000.00

00000000

s nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000000000000
Gaithersburg, MD
00 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Xention Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom 00 000.00 00000000000 000.00
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000 000.00
0000000 Venture Capital-Backed Cambridge, MA 000 00000000000 000
0000000000 Formerly VC-backed Cambridge, MA 00 0000 000000&0 0000
0000000 Venture Capital-Backed Stevenage, United Kingdom 00 00000 00000000000 00000
You’re viewing 5 of 28 competitors. Get the full list »

Xention Board Members (14)

Name Representing Role Since
Hugo Slootweg Self Board Member 000 0000
Keith McCullagh Ph.D Xention Chairman 000 0000
You’re viewing 2 of 14 board members. Get the full list »

Xention Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Xention Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Seroba Life Sciences Venture Capital Minority 000 0000 000000 0
Foresight Group PE/Buyout Minority 000 0000 000000 0
Gresham House Strategic Public Equity PE/Buyout Minority 000 0000 000000 0
ABN AMRO AAH.AS Investment Bank Minority 000 0000 000000 0
Omnes Capital PE/Buyout Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »